Peptides for respiratory and pulmonary health — beyond inhalers

Respiratory disease spans an enormous range — from episodic bronchospasm to relentlessly progressive scarring — and the conventional management hierarchy across that range is actually quite good in some areas and genuinely limited in others. Understanding where peptide research fits requires being honest about both of those things.

Asthma is a condition of airway inflammation, bronchospasm, and airway remodeling, with well-established phenotypes. Mild-to-moderate asthma managed with inhaled corticosteroids and short-acting bronchodilators represents some of the most evidence-dense pharmacology in medicine. The biologic era — dupilumab, mepolizumab, benralizumab, tezepelumab — has transformed outcomes for severe eosinophilic asthma, targeting specific inflammatory pathways (IL-4/IL-13, IL-5, thymic stromal lymphopoietin) in ways that have meaningfully reduced exacerbation rates and steroid burden for people with the right phenotype. The honest statement about asthma is that effective FDA-approved options exist across the severity spectrum, and the question is less often "is there a treatment" and more often "has the right treatment been matched to the right phenotype."

COPD — chronic obstructive pulmonary disease, driven primarily by smoking history and sometimes by occupational or environmental exposures — has a different trajectory. Long-acting muscarinic antagonists (LAMAs), long-acting beta-agonists (LABAs), and their combination slow the rate of decline and reduce exacerbations, but they don't reverse the underlying emphysematous destruction or airway remodeling. The structural damage is largely permanent. The challenge in COPD management is that most of the functional loss has already occurred by the time someone is diagnosed, and the foundational intervention — smoking cessation — remains the single most powerful lever available, particularly early in the course.

Pulmonary fibrosis occupies a different category still. Idiopathic pulmonary fibrosis is progressive scarring of lung parenchyma by an incompletely understood mechanism, and the antifibrotic agents pirfenidone and nintedanib slow progression but don't reverse it. Median survival from diagnosis has been extending with these agents, but the treatment trajectory is still one of managed decline rather than restoration. This is important context: in fibrotic lung disease, the gap between what people hope for and what medicine can currently offer is real and large.

Post-COVID pulmonary symptoms — the persistent breathlessness, the reduced exercise capacity, the chest tightness that can linger months after acute infection — represent a newer and not fully characterized category. Some people have measurable pulmonary function changes; others have normal spirometry with real symptoms and impaired cardiopulmonary exercise test results suggesting microvasculature or gas exchange issues. The mechanism is heterogeneous across patients and still being characterized, which means the treatment approaches are varied and often empiric.

Now to the peptide threads, with appropriate framing about where each sits on the evidence continuum.

VIP — vasoactive intestinal peptide — is where the respiratory peptide research has its most developed scientific foundation. VIP is an endogenous neuropeptide with substantial expression in the lung. It acts as a bronchodilator, a pulmonary vasodilator, and an anti-inflammatory agent in pulmonary tissue. The lung is one of the richest sites of VIP receptors in the body, which is not an accident: VIP appears to be a homeostatic regulator of pulmonary vascular tone and airway smooth muscle in normal physiology. Research in pulmonary arterial hypertension — a serious condition of elevated pressure in the lung vasculature — has found reduced VIP expression in lung tissue from PAH patients, and clinical research on inhaled VIP for pulmonary arterial hypertension has been conducted. Aviptadil, a synthetic VIP formulation, attracted significant attention during the COVID-19 pandemic when it was studied in ICU patients with acute respiratory distress, based on the hypothesis that VIP's anti-inflammatory and lung-protective properties might be relevant to the cytokine-driven lung injury pattern of severe COVID-19. The clinical evidence from those trials was mixed and the picture remains unresolved, but the interest highlighted how seriously the pulmonary research community takes VIP's mechanistic role in the lung. Separately, VIP's relevance to sarcoidosis — a granulomatous inflammatory condition that affects the lung among other organs — has been explored in research contexts. None of this has translated to a standard-of-care peptide protocol in pulmonary medicine, and VIP as a clinical compound carries complexity in route of administration and dosing that makes it distinct from the orally or subcutaneously administered research peptides more commonly discussed in functional medicine contexts.

Thymosin Alpha-1 is a thymic peptide with well-documented immune-modulating properties, historically researched for its ability to support T-cell function in immunocompromised contexts. It has approved uses in some countries (though not FDA-approved in the United States for any indication) for hepatitis B and C, and has been studied in contexts including cancer patients with impaired immune function and chronic infectious disease. The respiratory relevance lies in recurrent infection vulnerability: people with immunocompromise, frequent respiratory tract infections, or post-illness immune dysregulation represent a population where Thymosin Alpha-1 research has been done. The question of whether it has utility for otherwise healthy people with frequent respiratory infections — or in the long-COVID immune-dysregulation pattern — is being explored but not established. This is a compound with more clinical research behind it than most in this space, but not in ways that map cleanly to the general-population respiratory-support framing sometimes attached to it.

KPV — a tripeptide with anti-inflammatory properties — has been researched primarily in gut inflammation contexts, but the general mechanism of reducing inflammatory cytokine activity has relevance to airway inflammation in principle. Whether that principle translates to meaningful effect in airways specifically is not established by clinical evidence. The same is true of other anti-inflammatory peptides: the mechanistic logic is present, the clinical translation is not.

BPC-157 — body protection compound, originally isolated from gastric juice protein — has the broadest preclinical literature in this peptide class, with animal model research covering wound healing, gut protection, tendon repair, and angiogenesis. Preclinical research has explored potential lung-protective properties in models of specific insults, including some data on BPC-157 and lung tissue preservation in animal contexts. What the preclinical BPC-157 data represents in terms of human pulmonary benefit is genuinely unknown. The compound is researched as a compounded peptide and is not FDA-approved for any indication.

The post-COVID pulmonary context is worth addressing directly because it represents a population that is underserved by current standard protocols and therefore sometimes drawn toward adjunctive approaches. The post-COVID respiratory picture varies: some people have persistent small airway disease, some have microvasculature injury that affects gas exchange without obvious spirometric abnormality, some have autonomic dysfunction affecting their respiratory pattern, and some have residual inflammatory activity in lung tissue. The VIP research thread is arguably most relevant here given pulmonary vasodilation and anti-inflammatory mechanisms, but the evidence is not clinical evidence specific to this population. The Thymosin Alpha-1 immune-support rationale is also being explored for long-COVID contexts. What these represent is mechanistically motivated early research interest, not established protocols.

What honest framing looks like in respiratory medicine: the lungs are not a system where empiric experimentation is low-stakes. Respiratory disease progresses, sometimes irreversibly. The conventional management hierarchy exists for good reasons — inhaled corticosteroids for airway inflammation, bronchodilators for bronchospasm, antifibrotics for progressive fibrosis, biologics for the right asthma phenotypes — and the evidence supporting those choices is stronger than the evidence for any peptide approach in pulmonary medicine. Peptides in the respiratory space are at best adjunctive and potentially complementary to established management; they are not substitutes. The window during which intervention might prevent irreversible loss in conditions like COPD or IPF is real and limited, which means delayed or displaced treatment carries genuine cost.

Anyone with meaningful respiratory symptoms — reduced exercise tolerance, exertional breathlessness that is worsening, recurrent chest tightness, persistent post-infection respiratory impairment — deserves a pulmonology evaluation that characterizes the mechanism. Spirometry with diffusion capacity, sometimes CT imaging, sometimes cardiopulmonary exercise testing, and sometimes specific labs for inflammatory or fibrotic markers give a picture of what is actually happening that allows treatment to be matched to pathophysiology rather than symptoms. The peptide research threads are interesting and in some cases the underlying biology is well-founded; what they need is clinical evidence in pulmonary populations that currently doesn't exist. Your pulmonologist is the appropriate starting point, with the research landscape as context for a broader conversation about what might complement established management.